Jefferies raised the firm’s price target on Cigna to $422 from $402 and keeps a Buy rating on the shares. Accredo specialty was inherited through Cigna’s acquisition of ESI in 2018, but it is being highlighted now due to the pending loss-of-exclusivity cycle, which is “outsized,” and the fact that the new product pipeline continues to shift toward specialty, notes the analyst following meetings with Cigna CFO Brian Evanko.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CI:
- Cigna subsidiary sues FTC demanding withdrawal of PBM report
- Biden-Harris administration to require mental health coverage parity
- Election 2024: Where To Put Your Money Ahead of the Vote
- ESPN goes dark on DirecTV, Harris to oppose Nippon-U.S. Steel deal: Morning Buzz
- Cigna Reaffirms 2024 Earnings Projection to Analysts